News | 24 December 2021
Indian Pharmaceutical Market grew at 6.6 pc in November
Flattish volume growth and subdued new launches were key factors for last month
Flattish volume growth and subdued new launches were key factors for last month
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
The company has started manufacturing the Sputnik Light vaccine
Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response
The company will collaborate with U.S.-based colleagues to help life sciences companies improve commercial effectiveness
The Indian Council of Medical Research (ICMR), intends to enter into non-exclusive agreements with companies
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
TeleRay partners with Radiobotics, adding Artificial Intelligence to their pre-existing integrated best-in-class medical image and patient information distribution platform
The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research
EMA’s CHMP advice states that Paxlovid can be used for treatment of adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease
Since its launch, the medical devices park in Sultanpur has received overwhelming response with more than 50 companies lining up to set up their manufacturing or research and development units
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
The cash consideration for the acquisition is US$ 18 million.
The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation
During H1 FY2022, the revenues and operating profit margin (OPM) for ICRA sample set showed sharp improvement aided by volume uptick in Covid-19 and allied tests and also demand traction for non-Covid tests
Subscribe To Our Newsletter & Stay Updated
